StockWatch
·
SOLARA ACTIVE PHARMA SCIENCES · Q2 FY27 · THE VERDICT

33% Growth, But Margins Are Renting Space

Q2 delivered exceptional 33% YoY revenue growth and 382% PAT recovery—but ₹4.5 crore of that profit was a one-time equipment sale, and the margin gains rely on BASF supply disruptions that won't last. The street is still pricing in the ibuprofen risk.

Q2 FY27 resultsSOLARASolara Active Pharma Sciences Ltd23 Oct 2026 · 6 min read
Reported PAT

₹28.5 Cr

+382% YoY

Vizag equipment sale (one-time)

₹4.5 Cr

exceptional gain

Adjusted PAT

~₹24 Cr

organic profit

Base business EBITDA

₹77 Cr

23.6% margin vs 25% ±1% target

Where the profit came from

The ₹28.5 crore profit headline masks a critical detail: ₹4.5 crore came from selling idle ibuprofen equipment at the Vizag facility—a one-time monetization, not operating income. Strip that out, adjusted PAT is roughly ₹24 crore, a solid but more earthbound organic result versus the 382% pop on the screen. The real Q2 story is in the base business: ₹327 crore revenue (+37% YoY), ₹77 crore EBITDA, 23.6% margin. That's operationally excellent. But the gross margin sits at 47.2%, down 280 basis points year-over-year from prior 50%-plus, and management acknowledges that headwind will persist another 1–2 quarters.

We have not been able to fully recover as a pass-through mechanism due to this West Asia crisis… a headwind which, based on the current industry dynamic, probably this is something which we'll have to live with for at least one, two quarters more.

Claims versus what holds up

Management's Q2 on-call claims, graded against the delivered result

Q2 best quarter in ~5 years, 33% YoY revenue growth

₹417.3 Cr (+33.1% YoY), base +37%—exact match

Supported

EBITDA doubled, 118% YoY to ₹77 Cr

Base business EBITDA ₹77 Cr confirmed; consolidated includes ibuprofen drag

Supported (base business)

PAT ₹28.5 Cr, highest in 5 years, 382% YoY

₹28.5 Cr reported, but ₹4.5 Cr is one-time gain; adjusted ~₹24 Cr

Technically supported; inflated by one-time gain

Ibuprofen loss ₹9 Cr, narrowing, path to breakeven clear

Loss ₹9 Cr confirmed; but macro-driven (BASF supply, solvent prices), not structural; breakeven timing 'difficult to guess'

Overstated (macro-dependent)

Gross margin 47.2%, sustainable 52–55% range

47.2% confirmed; but down from 50%+ prior; customer power blocks pass-through; recovery unverified

Unverified (current compression unresolved)

Base business EBITDA margin 23.6% (vs 25% ±1% prior target)

23.6% delivered—at lower end of prior range

Achieved; margin recovery slower than expected

What changed on this call

  • Ibuprofen loss narrowing: ₹9 Cr Q2 vs ₹10–15 Cr quarterly guidance prior. Better than expected, but macro-driven (BASF supply, solvent spikes), not structural.

  • Strategic review timeline extended: Originally H1 FY27 (by Jan), now 12 weeks from Oct 16 (~mid-Jan 2027). Third extension. Signals decision complexity or stakeholder misalignment.

  • Base business EBITDA margin 23.6% vs prior 25% ±1% target. Within range but at lower end. Gross margin headwinds (customer power blocking pass-through) persist 1–2 more quarters.

  • DMF filing pace on track: 2 completed in FY27, targeting 5 annual. Valbenzazine filed for US; business case analysis underway. Regulatory execution solid.

  • Net debt reduction on track: ₹500 Cr (down 18% from ₹614 Cr), ND/EBITDA 1.8x vs 3.2x prior. H1 FY27 capex ₹20 Cr; ₹10–15 Cr/quarter pace maintained.

How the street is positioned

The stock trades at ₹611.55, down 64% from its all-time high and below both the 20-day and 50-day moving averages. The RSI at 38.5 is neutral—not oversold, not rallying. Volume is trending higher, consistent with institutional repricing. This is the market saying: well-executed Q2, but prove me the upside.

Foreign institutional investors (FII) are trimming. They held 11.52% in Q1 FY27, down from 14.63% a year ago—a 207-basis-point annual decline. Domestic institutions are flat at 3.74%. The promoter stake remains stable at 41.93%. This outflow pattern is the tell: good execution on Q2, but the ibuprofen drag, margin headwinds, and macro dependency haven't convinced foreigners the stock is a screaming buy at these prices.

Bulk deal activity (last six months) shows mostly algorithmic trading by JUNOMONETA and one PE exit by TPG Growth in July at ₹573.20. No promoter or insider selling near the highs—that's clean. But TPG's July exit below current spot suggests even PE holders aren't betting on a near-term re-rate. The market is waiting for clarity: either ibuprofen gets resolved (mid-Jan 2027) or it doesn't; either gross margin recovers or it stays compressed.

Risks, ranked by how much they should concern a holder

Where the quarter breaks down

Ibuprofen strategic review timeline (now mid-Jan 2027, 3rd extension)

Medium

If decision slips again or the chosen path (CRAMS, Vizag, sale) proves costly, Q3/Q4 capex or write-downs could surprise. The ₹9 Cr loss continues to drag EBITDA until resolved. Slippage = higher risk of forced asset impairment.

Gross margin recovery blocked by customer power

Medium

47.2% vs prior 50%+ is a structural squeeze on base-business EBITDA despite strong topline growth. If headwinds persist beyond 1–2 quarters or customer dynamics worsen, base margin target of 25% ±1% becomes unachievable. Volume growth then becomes the only margin-expansion lever.

Macro dependency (ibuprofen recovery relies on BASF supply disruption, solvent prices)

Medium

If BASF capacity returns to market or solvent prices normalize, ibuprofen loss widens back to ₹10–15 Cr/quarter guidance. Management explicit: 'difficult to guess' timing. This isn't structural cost control; it's a supply squeeze tailwind that reverses.

Strides customer concentration (₹104 Cr annualized, ~25% of revenue; receivables ₹160 Cr, 4x YoY)

Medium

Receivables spike from ₹63 Cr to ₹160 Cr explained as shipping/billing linearity, not credit terms. But a 4x jump deserves monitoring. If Strides diversifies supply or payment terms tighten, it's a ₹25–30 Cr topline and cash-flow headwind.

FII outflow (11.52% from 14.63% YoY, −207 bps)

Low-Medium

Indicates institutional skepticism on re-rate despite good Q2. Could flag concern on earnings visibility ahead of ibuprofen resolution. Not a bankruptcy signal, but a 'show me more' from serious money.

What to watch next
  • 1 · Ibuprofen strategic review conclusion (mid-Jan 2027)

    The deciding question: CRAMS repurposing, facility sale, or other? Clarity here will either unlock capex reallocation or trigger asset writedowns. This is the single biggest determinant of Q3 FY27 and FY28 credibility.

  • 2 · Gross margin recovery path (Q3 FY27 onwards)

    Monitor whether base-business gross margin starts to widen above 47.2% as West Asia raw material costs normalize and solvent prices fall. If still compressed in Q3, the 1–2 quarter headwind window may extend, pushing base EBITDA margin below the 25% ±1% target for longer.

  • 3 · Strides receivables normalization

    The ₹160 Cr FY27 Q2 spike is large. If it normalizes by Q3 (back toward ₹100 Cr range), the shipping linearity story holds. If it stays elevated or grows, Solara's working capital and cash generation become a concern.

The number to track from here

Forget reported PAT. Track adjusted (ex-one-time) EBITDA margin on the base business. That's the real health of the franchise. It delivered 23.6% in Q2 against a 25% ±1% target. If that margin stays flat or falls in Q3, it's a sign customer power and macro headwinds are the binding constraint, not operational excellence. If it ticks toward 24–25%, the turnaround narrative holds. Until ibuprofen is resolved and that margin path clears, Solara is a hold—well-managed, but not yet a conviction buy.

Q2 FY27 is steady execution, not a step-change. The base business is strong, debt is coming down, and operations are disciplined. But the reported profit is inflated by a one-time gain, and the margin gains rest on commodity tailwinds (BASF supply, solvent prices) that won't last forever. Ibuprofen remains a strategic overhang—the mid-Jan 2027 decision will be either clarifying or another disappointment. Until then, the stock has room to reprice if macro headwinds persist or ibuprofen resolution disappoints. The FII outflow and 64% drawdown from ATH suggest the market is already pricing in caution. Hold for clarity on margins and strategy; don't chase the topline growth alone.

Informational and educational content only. Not investment advice.